Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Fibrates Effect on Cardiovascular Risk Is Greater in Patients With High Triglyceride Levels or Atherogenic Dyslipidemia Profile: A Systematic Review and Meta-analysis

Bruckert, Eric, Labreuche, Julien, Deplanque, Dominique, Touboul, Pierre-Jean, Amarenco, Pierre · 2011 · Journal of Cardiovascular Pharmacology

Abstract

According to recently published data, fibrates may reduce the risk of major cardiovascular events. Whether patients with low high-density lipoprotein cholesterol (HDL-C), high triglyceride levels, or both may have additional benefits remains under debate.We performed a meta-analysis of the 5 large trials assessing the impact of fibrates on cardiovascular end points and providing information on low HDL-C and high triglyceride levels. Subgroups were determined according to values closest to predetermined cut-offs for both HDL-C and triglycerides (<35 and >200 mg/dL, respectively). Overall, 4671 patients (2401 in fibrate group and 2270 in placebo group) were classified as having an atherogenic dyslipidemia featuring low HDLC combined with high triglyceride levels. Across trials, the proportion of patients classified in this subgroup ranged from 11% to 33%. We found a significant difference in the magnitude of fibrate effect across dyslipidemia subgroups (P for between-group heterogeneity = 0.0002). A greater effect size was found in patients with high triglyceride levels or atherogenic dyslipidemia phenotype where fibrates were estimated to reduce the cardiovascular risk by 28% [95% confidence interval (CI), 15% to 39%; P < 0.001] or 30% (95% CI, 19% to 40%, P < 0.0001), respectively, but only by 6% (95% CI, 22% to 13%, P = 0.13) in nonatherogenic dyslipidemia patients. Targeting patients with high triglyceride levels or atherogenic dyslipidemia with fibrates may help reduce residual vascular risk.

Overview

Integrity signals

Registry

Crossref · 10.1097/fjc.0b013e318202709f

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 30 references

Cited by

See all 192

Metadata

Authors
Bruckert, E., Labreuche, J., Deplanque, D., Touboul, P.-J., & Amarenco, P.
Affiliations
Inserm (FR)
Venue
Journal of Cardiovascular Pharmacology
Published
2011-02
Volume
57
Issue
2
Pages
267-272
ISSN
0160-2446 (ISSN-L)
OpenAlex
W2071298734
Cited by
192
References
30
Citations by year
2026: 5 · 2025: 6 · 2024: 4 · 2023: 15 · 2022: 16 · 2021: 13 · 2020: 15 · 2019: 13 · 2018: 11 · 2017: 10 · 2016: 17 · 2015: 16 · 2014: 16 · 2013: 16 · 2012: 10
FWCI
1.94
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Cardiovascular Pharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
fibrates, cardiovascular risk, atherogenic dyslipidemia, low HDL cholesterol, cardiovascular events, subgroup analysis
MeSH terms
Cardiovascular Diseases, Humans, Risk Factors, Triglycerides, Dyslipidemias, Atherosclerosis, Fibric Acids

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fibrates Effect on Cardiovascular Risk Is Greater in Patients With High Triglyceride Levels or Atherogenic Dyslipidemia Profile: A Systematic Review and Meta-analysis. https://app.cochat.ai/papers/10.1097/fjc.0b013e318202709f
The paper
Bruckert, E., Labreuche, J., Deplanque, D., Touboul, P.-J., & Amarenco, P. (2011). Fibrates Effect on Cardiovascular Risk Is Greater in Patients With High Triglyceride Levels or Atherogenic Dyslipidemia Profile: A Systematic Review and Meta-analysis. Journal of Cardiovascular Pharmacology. https://doi.org/10.1097/fjc.0b013e318202709f

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.